semaglutide graves disease & Thyroid Issues: Safety & Medical Guidance – PlexusDx Functional Medicine for Grave's Disease

Type: Synthetic triple-agonist peptide Receptors Targeted: GLP1R, GIPR, and GCGR Mechanism of Action: Appetite suppression, enhanced insulin response, increased energy expenditure Delivery: Once-weekly subcutaneous injection Research Use: Preclinical and clinical studies in obesity, metabolic disorders, and type 2 diabetes Retatrutide is a next-generation multi-receptor peptide that leverages GLP1, GIP, and glucagon signaling to produce weight loss and metabolic benefits

If any tolerability issues are reported, consider reducing the dose

Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjth TV, Andreasen AH, Jensen CB, DeFronzo RA, for the NN8022-1922 Study Group

Comprender estos factores ayuda a establecer expectativas realistas y optimizar el tratamiento